Ischaemic Cardiomyopathy

Long-term Outcomes of Ventricular Tachycardia Ablation in Different Types of Structural Heart Disease

Ventricular tachycardia (VT) is a significant cause of morbidity and mortality in patients with structural heart disease (SHD). While implantable cardioverter-defibrillators (ICDs) have been shown to be effective in preventing sudden death due to ventricular arrhythmias, they are not able to prevent recurrent VT episodes. Antiarrhythmic drugs (AADs) have some demonstrated efficacy in preventing VT episodes, although options remain limited in patients with SHD and the degree of benefit is suboptimal.

Preventing Sudden Cardiac Death in Patients with Ischaemic Cardiomyopathy

Sudden cardiac arrest (SCA) can be defined as the abrupt cessation of cardiac activity due to an underlying cardiac cause, occurring instantaneously in a previously stable patient and in the absence of non-cardiovascular causes (e.g., trauma, intoxication, drowning, electrocution).1,2 SCA will lead to loss of consciousness within the minute due to insufficient cerebral perfusion. If no immediate action is taken to restore circulation – e.g., defibrillation – SCA will invariably lead to sudden cardiac death (SCD).

Prognostic Utility of Microvolt T-Wave Alternans in Risk Stratifying Patients with Ischemic Cardiomyopathy

Sudden cardiac death (SCD) is the leading cause of mortality in patients with ischemic heart disease and left ventricular dysfunction.1 The second Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) have shown that implantable cardioverter defibrillators (ICDs) reduce mortality in patients with ischemic heart disease and left ventricular ejection fractions (LVEF) <30% and <35%, respectively.2,3 Although ICD implantation may be cost-effective overall,4-7 wid

Multidetector-row Computed Tomography in the Evaluation of Heart Failure

The prevalence of heart failure and the resultant mortality has continued to rise despite increased understanding of the pathogenesis and improvement in management strategies.1 Left ventricular (LV) dysfunction is the final stage of most primary cardiovascular diseases, and greater severity is directly correlated with worse prognosis.